This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

NPS Pharmaceuticals Reports Third Quarter 2012 Financial Results And Reiterates Year-end Cash Guidance

     

 

NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)

                         
Three Months Ended Nine months ended
September 30, September 30,
2012 2011 2012 2011
 
Revenues:
Royalties $ 27,012 $ 24,483 $ 78,453 $ 70,244
Sale of royalty rights -- -- 25,000 --
Milestones and license fees 7 19 7 5,044
Product sales   --     99     --     99  
Total revenues   27,019     24,601     103,460     75,387  
 
Costs and expenses:
Cost of royalties -- -- -- 500
Cost of license fees -- 2 -- 2,540
Research and development 17,957 20,227 70,797 52,267
General and administrative   8,329     6,413     25,769     17,028  
Total operating expenses   26,286     26,642     96,566     72,335  
Operating income (loss) 733 (2,041 ) 6,894 3,052
Other (expense) income:
Interest income, net 64 70 224 260
Interest expense (4,444 ) (10,589 ) (14,445 ) (31,150 )
Other   323     211     795     225  
Total other expense, net   (4,057 )   (10,308 )   (13,426 )   (30,665 )
Loss before income tax expense (3,324 ) (12,349 ) (6,532 ) (27,613 )
 
Income tax expense   --     --     --     18  
Net loss   ($3,324 )   ($12,349 )   ($6,532 )   ($27,631 )

Net loss per common and potential common share:

Basic   ($0.04 )   ($0.14 )   ($0.08 )   ($0.35 )
Diluted   ($0.04 )   ($0.14 )   ($0.08 )   ($0.35 )
Weighted average common and potential common share:  
Basic   86,947     86,749     86,910     79,417  
Diluted   86,947     86,749     86,910     79,417  
 

 
NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

          September 30,2012         December 31,2011
Assets:
Cash, cash equivalents and marketable investment securities $118,723 $162,233
Account receivable 28,074 29,532
Other current assets 4,681 7,863
Property and equipment, net 4,097 4,346
Goodwill 9,429 9,429
Debt issuance costs, net 462 577
Total assets $165,466 $213,980
 
Liabilities and Stockholders’ Deficit:
Current liabilities $29,567 $43,603
Convertible notes 16,545 16,545
Non-recourse debt, less current portion* 159,400 192,085
Other long-term liabilities 6,695 7,863
Total liabilities 212,207 260,096
 
Common stock and additional paid-in capital 950,212 944,430
Accumulated other comprehensive income 29 (96)
Accumulated deficit (996,982) (990,450)
Total stockholders' deficit (46,741) (46,116)
Total liabilities and stockholders' deficit $165,466 $213,980
 
* Non-recourse debt secured by Sensipar ®/Mimpara ®, Preotact ® and REGPARA ® royalty revenue
 




5 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs